Related Experiment Videos
Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model
D Lemeteil1, F Roussel, L Favennec
1Department of Parasitology, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire, Rouen, France.
Abstract:
Cryptosporidium parvum causes life-threatening diarrhea in immunocompromised patients, especially those with AIDS. The efficiency of currently proposed anticryptosporidial therapies is limited or doubtful. In this report, molecular candidates for curative or preventive activity were investigated in an immunocompromised rat model that mimics severe human cryptosporidiosis. No significant anticryptosporidial activity was observed when using sulfadoxine-pyrimethamine, quinacrine, trimethoprim-sulfamethoxazole, bleomycin, elliptinium, daunorubicin, pentamidine, alpha-difluoro-methylornithine, diclazuril or N-methylglucamine. Vitamin A appeared to reduce oocyst shedding. Active agents included sinefungin (2-10 mg/kg/24 h), lasalocid A (2-10 mg/kg/24 h), metronidazole (25-50 mg/kg/24 h), and sulfadimethoxine (10-100 mg/kg/24 h). Sinefungin (10 mg/kg/24 h) and lasalocid A (10 mg/kg/24 h) displayed the highest anticryptosporidial activity.
Insights
This study evaluated anticryptosporidial agents in an immunocompromised rat model. Sinefungin and lasalocid A demonstrated the highest efficacy against Cryptosporidium parvum, offering potential new treatments.
Area of Science:
- Infectious Diseases
- Parasitology
- Pharmacology
Background:
- Cryptosporidium parvum infection causes severe diarrhea in immunocompromised individuals, including those with AIDS.
- Current therapies for cryptosporidiosis have limited or questionable effectiveness.
Purpose of the Study:
- To investigate molecular candidates for curative or preventive activity against Cryptosporidium parvum.
- To evaluate potential treatments in an immunocompromised rat model that simulates severe human cryptosporidiosis.
Main Methods:
- An immunocompromised rat model was used to test various anticryptosporidial agents.
- Compounds tested included sulfadoxine-pyrimethamine, quinacrine, metronidazole, sinefungin, and lasalocid A, among others.
- Oocyst shedding and overall anticryptosporidial activity were assessed.
Main Results:
- Most tested agents, including sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole, showed no significant anticryptosporidial activity.
- Vitamin A showed a potential to reduce oocyst shedding.
- Sinefungin and lasalocid A exhibited significant anticryptosporidial activity, with the highest efficacy observed at 10 mg/kg/24 h.
Conclusions:
- Sinefungin and lasalocid A are promising candidates for treating cryptosporidiosis.
- Further research into these agents may lead to more effective therapies for immunocompromised patients.